
Loading, please wait...

Loading, please wait...

L-tryptophan serves as a crucial aromatic amino acid with diverse applications in the pharmaceutical and food industries. However, achieving efficient L-tryptophan microbial production remains a complex task for bioengineers due to metabolic feedback regulation. Recently, a team of researchers successfully constructed a high-efficiency Escherichia coli cell factory by integrating systematic metabolic engineering with innovative high-throughput screening methods.
Initially, the researchers developed a tnaC-based biosensor to monitor intracellular amino acid levels. They coupled this tool with atmospheric and room temperature plasma (ARTP) mutagenesis. Consequently, this approach allowed the team to isolate high-performance chassis strains more effectively. Furthermore, the scientists reprogrammed central carbon metabolism to minimize carbon loss during fermentation. They channeled metabolic fluxes toward essential precursors like phosphoenolpyruvate (PEP) and erythrose-4-phosphate (E4P) to optimize the pathway.
To address pathway bottlenecks, the team utilized promoter engineering to refine genetic expression. This step balanced the intracellular supplies of L-glutamine, L-serine, and phosphoribosyl pyrophosphate (PRPP). As a result, the intervention yielded a significant 21.61% increase in L-tryptophan accumulation. Additionally, the researchers engineered product transport systems to improve efficiency. These modifications enhanced extracellular secretion while mitigating intracellular toxicity levels. Finally, the optimized strain (W-24) produced 50.83 g/L of L-tryptophan in a 5 L bioreactor. Therefore, this framework provides a scalable strategy for the industrial production of various valuable aromatic compounds.
This breakthrough significantly lowers the cost and environmental impact of producing pharmaceutical-grade L-tryptophan. Consequently, it ensures a more stable and affordable supply of precursors for medications treating sleep disorders and depression.
The biosensor acts as a real-time monitor for tryptophan levels within the bacterial cell. It enables high-throughput screening, which allows researchers to identify the most productive genetic mutants during the evolution process with high precision.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or endorse any specific manufacturing practice. Refer to the latest local and national guidelines for clinical practice.
References
1. Zhu R et al. Biosensor-driven evolution and metabolic engineering of an Escherichia coli cell factory for L-tryptophan production. Microb Cell Fact. 2026 May 19. doi: 10.1186/s12934-026-03028-4. PMID: 42157063.
2. Huang J, et al. Improvement of L-Tryptophan Production in Escherichia coli Using Biosensor-Based, High-Throughput Screening and Metabolic Engineering. Molecules. 2025 May 07. doi: 10.3390/molecules30092244.
3. Chen X, et al. Optimizing L-Tryptophan Production in Escherichia coli through Redox Balancing and Metabolomics Analysis. Front Bioeng Biotechnol. 2024 Oct 12. doi: 10.3389/fbioe.2024.1489211.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers engineered an E. coli cell factory using biosensors to achieve high-yield L-tryptophan production, marking a major step for the pharmaceutical i...
3 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today